Concepedia

Roberto Luksch

RL

140

Publications

7.1K

Citations

50

H-Index

1990

Active since

Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori(Current)

Istituto Giannina Gaslini

University of Padua

Istituti di Ricovero e Cura a Carattere Scientifico

University of Milan

Roberto Luksch is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, radiation oncology, and oncology.

ORCID

Top concepts

Publications per year

1990–2024

140

Publications

140

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

, , +7

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

, , +8

Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.

Alberto Garaventa, Roberto Luksch, M. S. Lo Piccolo et al. · PubMed · 2003 · 189 citations

High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma

Maura Massimino, Filippo Spreafico, Graziella Cefalo et al. · Journal of Clinical Oncology · 2002 · 175 citations

Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma

Lorenza Gandola, Maura Massimino, Graziella Cefalo et al. · Journal of Clinical Oncology · 2008 · 173 citations · Full text

Rows per page

1–5 of 140